THE BRITISH COLUMBIA SACUBITRIL-VALSARTAN REGISTRY: RATIONALE AND BASELINE DEMOGRAPHICS

摘要

BACKGROUND: Sacubitril-valsartan is approved in Canada for treatment of heart failure (HF) with reduced ejection fraction based on results from the landmark PARADIGM-HF Trial. There is a paucity of real world data describing the impact of this novel therapy on healthcare utilization (HCU) including healthcare provider visits, the need for additional diagnostic imaging/laboratory testing as well as potential avoidance of CRT/ICD. To measure the system impact of sacubitril-valsartan on HF care in BC, Cardiac Services BC and BC's Heart Failure Network have created a Provincial registry to identify and track outcomes for patients initiated on this therapy.